Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening

          -  Histologically or cytologically documented advanced or metastatic solid tumors for
             which established therapy either does not exist or has proven ineffective or
             intolerable

          -  Life expectancy greater than or equal to (>=) 12 weeks

          -  Adequate hematologic and end organ function

          -  For female participants of childbearing potential and male participants with partners
             of childbearing potential, agreement (by participant and/or partner) to use highly
             effective forms of contraception and to continue its use for the duration of the study
             and for 4 months after last dose of study treatment (for females) and 6 months after
             last dose of study treatment (for males)

        Exclusion Criteria:

          -  Prior anti-cancer therapy that fulfills the following criteria: a total of more than
             three (Arms A and B) or two (Arms C and D) prior cytotoxic chemotherapy regimens,
             high-dose chemotherapy requiring stem-cell support, and irradiation to >=25 percent
             (%) of bone marrow-bearing areas

          -  Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy,
             oral contraceptives, or gonadotropin-releasing hormone (GnRH) agonists or antagonists
             for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except
             palliative radiation to bony metastases), or herbal therapy as cancer therapy within 4
             weeks prior to initiation of ipatasertib. Exceptions are kinase inhibitors approved by
             local regulatory authorities, which may be used within 2 weeks prior to initiation of
             ipatasertib, provided that any clinically-relevant drug-related toxicity has
             completely resolved and prior approval is obtained from the Medical Monitor

          -  Palliative radiation to bony metastases within 2 weeks prior to initiation of
             ipatasertib

          -  History of Type 1 or Type 2 diabetes requiring regular medication

          -  Grade >= 2 heart failure or history of unstable angina

          -  History of clinically significant ventricular arrhythmias or active ventricular
             arrhythmia requiring medication

          -  For Arm D only: History of seizure, unexplained loss of consciousness, transient
             ischemic attack within 12 months of enrollment, cerebral vascular accident, and any
             brain metastases